Abstract Library

#4363 61Cu-NODAGA-LM3 for the detection of neuroendocrine tumours: Preliminary results of the COPPER PET in NET trial, a randomised, crossover, readers blind, phase I/II non-inferiority study

Introduction: Currently approved PET tracers, Gallium-68 or Copper-64 labelled somatostatin receptor (SST) agonists (NETSPOT®, SOMAKIT® and Detecnet™), for imaging well-differentiated gastroenteropancreatic and bronchopulmonary neuroendocrine tumours (NET) have limitations. Radiolabelled SST antagonists offer superior imaging properties over agonists, and the combination with Copper-61, an unexplored PET isotope with a 3.33-hour half-life and favourable production characteristics, could be promising.

Conference:

Presenting Author: Nicolas G

Authors: Nicolas G, Chirindel A, Kaul F, Rommers N, Johayem A,

Keywords: Somatostatin Receptor PET/CT, Well-differentiated NEN, gastroenteropancreatic NET, bronchopulmonary NET, randomised controlled clinical trial, somatostatin receptor antagonist,

#1883 Utility of a Circulating NET mRNA Gene Signature for Defining Bronchopulmonary Neuroendocrine Neoplasia and Evaluating Disease Progression

Introduction: Bronchopulmonary NETs (BPNETs) exhibit indolent to aggressive behavior. Imaging, histology and biochemistry are limited in accurately defining malignancy or progression. A blood based NET multigene test is effective in diagnosing GEP-NET progression and therapy response.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Kidd M

Authors: Lewczuk A, Chung K, Kolasińska-Ćwikła A, Ćwikła J, Kidd M,

Keywords: NET,

#1571 Blood Gene Transcript Analysis Diagnoses Bronchopulmonary NETs and Identifies Progressive Disease

Introduction: Broncho-Pulmonary (BP) NETs are pulmonary neoplasms with indolent to aggressive behavior. Imaging, histology and biochemistry are limited in defining malignancy or progression

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Lewczuk A

Authors: Lewczuk A, Chung K, Kolasińska-Ćwikła A, Cwikła J, Kidd M,

Keywords: PCR,

#494 Diagnostic Features and Management Outcomes in Bronchopulmonary Neuroendocrine Tumors: A Clinical Study of 116 Patients

Introduction: Bronchopulmonary neuroendocrine tumors are classified into: typical carcinoids (TC), atypical carcinoids (AC), large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC).

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Pericleous M, Toumpanakis C, Lumgair H, Reiner J, Marelli L,

Keywords: bronchopulmonary NETs, atypical carcinoid, typical carcinoid,